Gut Microbial Metabolites in Obesity, NAFLD and T2DM

Overview

Journal Nat Rev Endocrinol

Specialty Endocrinology

Date 2019 Jan 24

PMID 30670819

Citations 538

Authors

Emanuel E Canfora

Ruth C R Meex

Koen Venema

Ellen E Blaak

Affiliations

Soon will be listed here.

Abstract

Evidence is accumulating that the gut microbiome is involved in the aetiology of obesity and obesity-related complications such as nonalcoholic fatty liver disease (NAFLD), insulin resistance and type 2 diabetes mellitus (T2DM). The gut microbiota is able to ferment indigestible carbohydrates (for example, dietary fibre), thereby yielding important metabolites such as short-chain fatty acids and succinate. Numerous animal studies and a handful of human studies suggest a beneficial role of these metabolites in the prevention and treatment of obesity and its comorbidities. Interestingly, the more distal colonic microbiota primarily ferments peptides and proteins, as availability of fermentable fibre, the major energy source for the microbiota, is limited here. This proteolytic fermentation yields mainly harmful products such as ammonia, phenols and branched-chain fatty acids, which might be detrimental for host gut and metabolic health. Therefore, a switch from proteolytic to saccharolytic fermentation could be of major interest for the prevention and/or treatment of metabolic diseases. This Review focuses on the role of products derived from microbial carbohydrate and protein fermentation in relation to obesity and obesity-associated insulin resistance, T2DM and NAFLD, and discusses the mechanisms involved.

Citing Articles

Circulating short-chain and branched short-chain fatty acids and the risk of incident type 2 diabetes: findings from the 4C study.

Wang S, Lin H, Jia X, Lin Y, Hu C, Li M Life Metab. 2025; 4(2):loaf001.

PMID: 40078932 PMC: 11897982. DOI: 10.1093/lifemeta/loaf001.

Gut microbiota therapy in gastrointestinal diseases.

Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman S Front Cell Dev Biol. 2025; 13:1514636.

PMID: 40078367 PMC: 11897527. DOI: 10.3389/fcell.2025.1514636.

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.

Differential effects of high-fat diet on salivary and gut microbiota.

Bai J, Tian Y, Lu Y, Chen Y, Yu M, Gao X Front Cell Infect Microbiol. 2025; 15:1547555.

PMID: 40066066 PMC: 11891374. DOI: 10.3389/fcimb.2025.1547555.

Impact of Short-Chain Fatty Acids on Glucose, Fatty Acid and Leucine Metabolism in Primary Human Myotubes.

Tingstad R, Witczak O, Beajani S, Seo S, Lovsletten N, Skagen C Endocrinol Diabetes Metab. 2025; 8(2):e70042.

PMID: 40051343 PMC: 11885951. DOI: 10.1002/edm2.70042.

References

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

Seuring T, Archangelidi O, Suhrcke M . The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015; 33(8):811-31. PMC: 4519633. DOI: 10.1007/s40273-015-0268-9. View

Tremmel M, Gerdtham U, Nilsson P, Saha S . Economic Burden of Obesity: A Systematic Literature Review. Int J Environ Res Public Health. 2017; 14(4). PMC: 5409636. DOI: 10.3390/ijerph14040435. View

Corpeleijn E, Saris W, Blaak E . Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev. 2009; 10(2):178-93. DOI: 10.1111/j.1467-789X.2008.00544.x. View

Shulman G . Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(12):1131-41. DOI: 10.1056/NEJMra1011035. View

Reilly S, Saltiel A . Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017; 13(11):633-643. DOI: 10.1038/nrendo.2017.90. View

Stinkens R, Goossens G, Jocken J, Blaak E . Targeting fatty acid metabolism to improve glucose metabolism. Obes Rev. 2015; 16(9):715-57. DOI: 10.1111/obr.12298. View

Backhed F, Ding H, Wang T, Hooper L, Koh G, Nagy A . The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101(44):15718-23. PMC: 524219. DOI: 10.1073/pnas.0407076101. View

10.

Ley R, Turnbaugh P, Klein S, Gordon J . Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022-3. DOI: 10.1038/4441022a. View

11.

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G . Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500(7464):541-6. DOI: 10.1038/nature12506. View

12.

Dao M, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger E . Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2015; 65(3):426-36. DOI: 10.1136/gutjnl-2014-308778. View

13.

Cani P, Amar J, Iglesias M, Poggi M, Knauf C, Bastelica D . Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56(7):1761-72. DOI: 10.2337/db06-1491. View

14.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

15.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

16.

Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee Y, De Vadder F, Arora T . Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella. Cell Metab. 2015; 22(6):971-82. DOI: 10.1016/j.cmet.2015.10.001. View

17.

De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A . Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014; 156(1-2):84-96. DOI: 10.1016/j.cell.2013.12.016. View

18.

Cani P, Joly E, Horsmans Y, Delzenne N . Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr. 2005; 60(5):567-72. DOI: 10.1038/sj.ejcn.1602350. View

19.

Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F . From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016; 165(6):1332-1345. DOI: 10.1016/j.cell.2016.05.041. View

20.

Frost G, Sleeth M, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L . The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014; 5:3611. PMC: 4015327. DOI: 10.1038/ncomms4611. View